Exosomes combined with biomaterials in the treatment of spinal cord injury
Front. Bioeng. Biotechnol., 2023 · DOI: 10.3389/fbioe.2023.1077825 · Published: March 13, 2023
Simple Explanation
Spinal cord injury (SCI) is a serious condition often leading to sensory and motor dysfunction. Current treatments have limitations. This paper reviews the potential of using exosomes, tiny vesicles secreted by cells, combined with biomaterials to treat SCI. Exosomes have advantages such as small size and low immunogenicity, allowing them to cross the blood-spinal cord barrier. Biomaterial scaffolds can help deliver and fix exosomes to the injury site, improving their survival rate. The review explores different sources of exosomes, various biomaterials, and the progress of combining them for SCI treatment, also noting challenges and future prospects of this therapeutic approach.
Key Findings
- 1Stem cell-derived exosomes have anti-inflammatory effects and can play a role in SCI treatment.
- 2Combining biomaterial scaffolds and exosomes can improve exosome delivery and survival at the injury site.
- 3Biomaterial scaffolds should have appropriate porosity, permeability, cytocompatibility, biodegradability, and low immunogenicity.
Research Summary
Practical Implications
Improved Exosome Delivery
Biomaterials enhance exosome retention and controlled release at the injury site.
Enhanced Tissue Regeneration
The combination promotes nerve regeneration, reduces inflammation, and improves motor function recovery.
Clinical Translation Potential
The review highlights the potential for clinical application of exosome-biomaterial combinations in SCI treatment.
Study Limitations
- 1Lack of standardized exosome isolation and purification methods.
- 2Absence of unified international standards for exosome purification and safety.
- 3Limited number of related studies and uniform standards for graft transplantation timing.